45 results on '"Calculli, G."'
Search Results
2. Acute Myocarditis After Black Widow Spider Bite: A Case Report
- Author
-
Piscopo, A., Massari, F., Scicchitano, P., Sanasi, M., De Palo, M., Caldarola, P., Liccese, M., and Calculli, G.
- Published
- 2020
- Full Text
- View/download PDF
3. C21 A FLOATING THROMBUS IN THE ASCENDING AORTA, AS A COMPLICATION OF A PERCUTANEOUS CORONARY ANGIOGRAPHY
- Author
-
Cortese, F, primary, Di Marino, S, additional, Calculli, G, additional, and Costantino, M, additional
- Published
- 2023
- Full Text
- View/download PDF
4. P163 THE ELECTROCARDIOGRAPHIC CHANGES ASSOCIATED WITH HYPOTHERMIA: THE OSBORN WAVE
- Author
-
Costantino, M, primary, Calculli, G, additional, Stolfi, L, additional, and Cortese, F, additional
- Published
- 2023
- Full Text
- View/download PDF
5. How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study
- Author
-
De Luca L., Colivicchi F., Meessen J., Uguccioni M., Piscione F., Bernabo P., Lardieri G., Granatelli A., Gabrielli D., Gulizia M. M., Silverio A., Benvenga R. M., Mascia F., Fusco A., Cicala S., Oltrona Visconti L., Marinoni B., Canosi U., Cirillo P., Trimarco B., Ziviello F., Grosseto D., Menozzi M., Mezzena D., Mauro C., Sasso A., Bellis A., Calabro P., Gragnano F., Cesaro A., Venturelli V., Porretta V., Borrelli N., Indolfi C., De Rosa S., Torella D., Morici N., Molfese M., Della Rovere F., Caiffa T., Moretto G., Grippo G., Di Vincenzo E., Lucisano L., Pennacchi M., Geraci G., Sanfilippo N., Ledda A., Di Lenarda A., Cherubini A., Russo G., Piemonte F., Di Donato A., Carraturo A., Villari B., Ciampi Q., Contaldi C., Pacher V., Corrada E., Cattani D., Nassiacos D., Meloni S., Barco B., Bonmassari R., Bertoldi A., Tedoldi F., Cannone M., Valenti G., Musci R. L., Caldarola P., Locuratolo N., Sublimi Saponetti L., Gentili L., Maiandi C., Caputo M., Capparuccia C. A., Tonella T., Massari F. M., Lupi A., Tessitori M., Montano M., Scaglione A., Torri A., Tortorella G., Navazio A., Cemin R., Latina L., Briguglia D., Marino R., Scalvini S., Zanelli E., Paganini V., Riboni G., Leiballi E., Della Mattia A., Imperadore F., Tespili M., Santangelo G., Parravicini U., Dellavesa P., Testa R., Venturini E., Feola M., Testa M., Crisci V., Tramontana M., Robiglio L., Varbella F., Meynet I., Galati A., Maddaluna A., Bilato C., Loddo I., Licciardello G., Cassaniti L., Scherillo M., Formigli D., Marullo L., Chianese L., Paolillo C., De Santis A. P. A., Brunetti N. D., Bottigliero D., Della Bona R., Giannico M. B., Tramarin R., Lucibello S., Perna G. P., Marini M., Colavita A. R., Raziliop A., Francese G. M., Mariani M., Collauto F., D'Urbano M., Naio R., Ando G., Saporito F., Assanelli E. M., Cabiati A., Crivaro A., Alberti S., Marchese I., Nejat T., Refice S., Raino R., Aiello A., Cristinziani G. R., Barilla F., Iorio R., Mascelli G., Tartaglione S. N., Di Chiara G., D'Andrea D., Antonicelli R., Malatesta G., Di Mario C., Mattesini A., Tramontana L., Conti S., Sommariva L., Celestini A., Amico F., Giubilato S., Amico A. F., De Filippis M., Pasini G. F., Triggiani M., Ferrara V., Cappetti S., Carugo S., Lucreziotti S., Persico M., Gizzi G., Cipolla T., Caronia A., Buia E., Pastori P., Scarpignato M., Biscottini E., Poletti F., Vimercati C., Pirola R., Barbieri E., Dugo C., De Cesare N., De Benedictis M. L., Ruggeri A., Campana C., Bonura S., Vigna C., Marchese N., Partesana N. G., Bandini P., Farinola G., Santoro D., Cassadonte F., Calabro F., Sansoni M., Abrignani M. G., Bonura F., Benvenuto M., Liso A., Passero T., Mori I., Pozzoni B., Prati F., Finocchiaro M. L., Tufano N., Miserrafiti B., Lacquaniti V., Del Piccolo F., Mohamad B., Spinnler M. T., Bovolo V., Rebulla E., Pieri M., Paloscia L., Di Clemente D., Mazzucco G., Micanti A., Peci P., Ornago O., Proietti F., Michisanti M., Reverzani A., Donatini A., Costa P., Russo S., Franceschini Grisolia E., Mario L., Di Palma F., Dell'Aquila F., Maestroni A., Caico S. I., De Caro G., Attianese L., Perotti S., Cotti Cometti V., Astengo D., Guerri E., Cianflone D., Maranta F., Esposito N., Malvezzi Caracciolo D'Aquino M., Caliendo L., Ricci C., Ceruso C. P., Lanteri S., Serdoz R., Bruno E., De Matteis C., Campagnuolo C., Ammirati M. A., Corrado V. M., Amado Eleas M. A., Fattore L., Ippoliti C., Turiano G., Piergentili C., Chiarella F., Capogrosso P., Perotti M., Di Marco S., Sibilio G., Di Lorenzo L., Aurelio A., Ramondo A. B., Zanna D., Cernetti C., Napolitano G., Negroni S., Alessandri N., Rigo F., Giusti F., Casu G., Vicentini A., Calculli G., Fera M. S., Lettica G. V., Vagheggini G., Piti A., Porfidia A., Di Leo A., Ravera A., Ciotta E., Sacca S., Silvestri O., Isidori S., Natali P., Anselmi M., Testa L., Antonelli A., Tavasci E., Furgi G., Lavorgna A., Gasparetto N., Bisceglia T., De Luca, L., Colivicchi, F., Meessen, J., Uguccioni, M., Piscione, F., Bernabo, P., Lardieri, G., Granatelli, A., Gabrielli, D., Gulizia, M. M., Silverio, A., Benvenga, R. M., Mascia, F., Fusco, A., Cicala, S., Oltrona Visconti, L., Marinoni, B., Canosi, U., Cirillo, P., Trimarco, B., Ziviello, F., Grosseto, D., Menozzi, M., Mezzena, D., Mauro, C., Sasso, A., Bellis, A., Calabro, P., Gragnano, F., Cesaro, A., Venturelli, V., Porretta, V., Borrelli, N., Indolfi, C., De Rosa, S., Torella, D., Morici, N., Molfese, M., Della Rovere, F., Caiffa, T., Moretto, G., Grippo, G., Di Vincenzo, E., Lucisano, L., Pennacchi, M., Geraci, G., Sanfilippo, N., Ledda, A., Di Lenarda, A., Cherubini, A., Russo, G., Piemonte, F., Di Donato, A., Carraturo, A., Villari, B., Ciampi, Q., Contaldi, C., Pacher, V., Corrada, E., Cattani, D., Nassiacos, D., Meloni, S., Barco, B., Bonmassari, R., Bertoldi, A., Tedoldi, F., Cannone, M., Valenti, G., Musci, R. L., Caldarola, P., Locuratolo, N., Sublimi Saponetti, L., Gentili, L., Maiandi, C., Caputo, M., Capparuccia, C. A., Tonella, T., Massari, F. M., Lupi, A., Tessitori, M., Montano, M., Scaglione, A., Torri, A., Tortorella, G., Navazio, A., Cemin, R., Latina, L., Briguglia, D., Marino, R., Scalvini, S., Zanelli, E., Paganini, V., Riboni, G., Leiballi, E., Della Mattia, A., Imperadore, F., Tespili, M., Santangelo, G., Parravicini, U., Dellavesa, P., Testa, R., Venturini, E., Feola, M., Testa, M., Crisci, V., Tramontana, M., Robiglio, L., Varbella, F., Meynet, I., Galati, A., Maddaluna, A., Bilato, C., Loddo, I., Licciardello, G., Cassaniti, L., Scherillo, M., Formigli, D., Marullo, L., Chianese, L., Paolillo, C., De Santis, A. P. A., Brunetti, N. D., Bottigliero, D., Della Bona, R., Giannico, M. B., Tramarin, R., Lucibello, S., Perna, G. P., Marini, M., Colavita, A. R., Francese, G. M., Mariani, M., Collauto, F., D'Urbano, M., Naio, R., Ando, G., Saporito, F., Assanelli, E. M., Cabiati, A., Crivaro, A., Alberti, S., Marchese, I., Nejat, T., Refice, S., Aiello, A., Cristinziani, G. R., Barilla, F., Iorio, R., Mascelli, G., Tartaglione, S. N., Di Chiara, G., D'Andrea, D., Antonicelli, R., Malatesta, G., Di Mario, C., Mattesini, A., Tramontana, L., Conti, S., Sommariva, L., Celestini, A., Amico, F., Giubilato, S., Amico, A. F., De Filippis, M., Pasini, G. F., Triggiani, M., Ferrara, V., Cappetti, S., Carugo, S., Lucreziotti, S., Persico, M., Gizzi, G., Cipolla, T., Caronia, A., Buia, E., Pastori, P., Scarpignato, M., Biscottini, E., Poletti, F., Vimercati, C., Pirola, R., Barbieri, E., Dugo, C., De Cesare, N., De Benedictis, M. L., Ruggeri, A., Campana, C., Bonura, S., Vigna, C., Marchese, N., Partesana, N. G., Bandini, P., Farinola, G., Santoro, D., Cassadonte, F., Calabro, F., Sansoni, M., Abrignani, M. G., Bonura, F., Benvenuto, M., Liso, A., Passero, T., Mori, I., Pozzoni, B., Prati, F., Finocchiaro, M. L., Tufano, N., Miserrafiti, B., Lacquaniti, V., Del Piccolo, F., Mohamad, B., Spinnler, M. T., Bovolo, V., Rebulla, E., Pieri, M., Paloscia, L., Di Clemente, D., Mazzucco, G., Micanti, A., Peci, P., Ornago, O., Proietti, F., Michisanti, M., Reverzani, A., Donatini, A., Costa, P., Russo, S., Franceschini Grisolia, E., Mario, L., Di Palma, F., Dell'Aquila, F., Maestroni, A., Caico, S. I., De Caro, G., Attianese, L., Perotti, S., Cotti Cometti, V., Astengo, D., Guerri, E., Cianflone, D., Maranta, F., Esposito, N., Malvezzi Caracciolo D'Aquino, M., Caliendo, L., Ricci, C., Ceruso, C. P., Lanteri, S., Serdoz, R., Bruno, E., De Matteis, C., Campagnuolo, C., Ammirati, M. A., Corrado, V. M., Amado Eleas, M. A., Fattore, L., Ippoliti, C., Turiano, G., Piergentili, C., Chiarella, F., Capogrosso, P., Perotti, M., Di Marco, S., Sibilio, G., Di Lorenzo, L., Aurelio, A., Ramondo, A. B., Zanna, D., Cernetti, C., Napolitano, G., Negroni, S., Alessandri, N., Rigo, F., Giusti, F., Casu, G., Vicentini, A., Calculli, G., Fera, M. S., Lettica, G. V., Vagheggini, G., Piti, A., Porfidia, A., Di Leo, A., Ravera, A., Ciotta, E., Sacca, S., Silvestri, O., Isidori, S., Natali, P., Anselmi, M., Testa, L., Antonelli, A., Tavasci, E., Furgi, G., Lavorgna, A., Gasparetto, N., Bisceglia, T., Raziliop, A., and Raino, R.
- Subjects
Male ,Multivariate analysis ,Time Factors ,medicine.medical_treatment ,Myocardial Infarction ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Cardiologists ,post‐MI ,030212 general & internal medicine ,Myocardial infarction ,Prospective Studies ,Registries ,intervention ,risk ,Dual Anti-Platelet Therapy ,focused update ,ticagrelor keywords plus:coronary-artery-disease ,Atrial fibrillation ,General Medicine ,clopidogrel ,dual antiplatelet therapy ,percutaneous coronary intervention ,post-mi ,secondary prevention ,dapt score ,duration ,management ,Middle Aged ,Clopidogrel ,Treatment Outcome ,Female ,Cardiology and Cardiovascular Medicine ,Ticagrelor ,Human ,medicine.drug ,medicine.medical_specialty ,animal structures ,Time Factor ,Clinical Investigations ,Cardiologist ,Drug Administration Schedule ,Follow-Up Studie ,ticagrelor ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Aged ,Aspirin ,post-MI ,Follow-Up Studies ,Platelet Aggregation Inhibitors ,Patient Selection ,business.industry ,Platelet Aggregation Inhibitor ,Percutaneous coronary intervention ,medicine.disease ,Prospective Studie ,Conventional PCI ,Observational study ,business - Abstract
Background Current guidelines suggest to consider dual antiplatelet therapy (DAPT) continuation for longer than 12 months in selected patients with myocardial infarction (MI). Hypothesis We sought to assess the criteria used by cardiologists in daily practice to select patients with a history of MI eligible for DAPT continuation beyond 1 year. Methods We analyzed data from the EYESHOT Post-MI, a prospective, observational, nationwide study aimed to evaluate the management of patients presenting to cardiologists 1 to 3 years from the last MI event. Results Out of the 1633 post-MI patients enrolled in the study between March and December 2017, 557 (34.1%) were on DAPT at the time of enrolment, and 450 (27.6%) were prescribed DAPT after cardiologist assessment. At multivariate analyses, a percutaneous coronary intervention (PCI) with multiple stents and the presence of peripheral artery disease (PAD) resulted as independent predictors of DAPT continuation, while atrial fibrillation was the only independent predictor of DAPT interruption for patients both at the second and the third year from MI at enrolment and the time of discharge/end of the visit. Conclusions Risk scores recommended by current guidelines for guiding decisions on DAPT duration are underused and misused in clinical practice. A PCI with multiple stents and a history of PAD resulted as the clinical variables more frequently associated with DAPT continuation beyond 1 year from the index MI.
- Published
- 2019
6. Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study
- Author
-
De Luca, Leonardo, Leonardi, Sergio, Smecca, Ignazio Maria, Formigli, Dario, Lucci, Donata, Gonzini, Lucio, Tuccillo, Bernardino, Olivari, Zoran, Gulizia, Michele Massimo, Bovenzi, Francesco Maria, De Servi, Stefano, Caporale, R., Cavallini, C., Ceravolo, R., Lupi, A., Musumeci, G., Rakar, S., Maggioni, A. P., Lorimer, A., Orsini, G., Fabbri, Giorgio, Bianchini, E., Abrignani, M. G., Bonura, F., Trimarco, B., Galasso, Giorgia, Misuraca, G., Manes, M. T., Irace, Lorenzo, Totis, O., Ledda, A., Mauro, C., Boccalatte, M., Iliceto, S., Cacciavillani, L., Savonitto, S., Tortorella, G., Esposito, L., DE ROSA, Paolo, Calabrò, P., Bianchi, R., Napoletano, C., Lalla Piccioni, L., Pavesi, P. C., Boni, Allegra, Merenda, R., Wolff, S., De Ferrari, G. M., Camporotondo, R., Gambino, Paolo, Cutaia, A., Picariello, C., Cemin, R., Chiarella, F., Grazioli Gauthier, L., Mircoli, L., Del Pinto, M., Finocchiaro, M. L., Scioli, R., Farina, R., Naddeo, C., Scherillo, M., Santopietro, S., Metra, M., Costa, F., Calculli, G., Troito, G., Pennisi, V., Adornato, E. M. F., Pirelli, S., Fadin, B. M., Di Biase, M., Ieva, R., Zuin, G., Sanfilippo, N., Mancuso, LAURA CATERINA, Pani, Luisa Anna, Serra, Eleonora, Marenzi, G., Assanelli, E. M., Ansalone, G., Cacciotti, L., Morocutti, G., Fresco, C., Berti, S., Paradossi, U., Bozzano, A., Mauro, A., Noussan, P., Zanini, P., Bolognese, L., Falsini, G., Costa, P., Manca, G., Caldarola, P., Locuratolo, N., Cipolla, T., Becchina, M., Cocco, Gabriele, Scalera, G., Stefanelli, S., Giunta, N., Sinagra, G., Meloni, L., Lai, O., Chiaranda, G., Luca, G., Sleiman Helou, J., Biscottini, E., Magliari, F., Callerame, M., Uguccioni, M., Pugliese, M., Sanchez, F., Tartaglione, S., Ignone, G., Mavilio, G., Mantovan, R., Bini, R., Caico, S. I., Demolli, V., Proietti, F., Michisanti, M., Musmeci, G., Cantamessa, P., Sicuso, G., Micalef, S. S., Accogli, M., Zaccaria, MICHELA MARIA, Caputo, M., Di Paolo, G., Piatti, L., Farina, A., Vicinelli, P., Paloscia, L., Di Clemente, D., Felis, S., Castini, D., Rota, C., Casu, Gabriella, Bonano, S., Margheri, M., Ricci Lucchi, G., Serdoz, R., Proietti, P., Autore, C., Conti, E., Russo, V., Orlando, P., Ramondo, A. B., Bontorin, M., Marcolongo, M., Marrara, F., Maestroni, A., Vitti, P., Rodella, P., Bonetti, P., Elia, M., Lumare, R., Politi, A., Gritti, S., Poletti, F., Mafrici, A., Fusco, R., Bongo, A. S., Bacchini, S., Gasparetto, V., Ferraiuolo, G., Campana, C., Bonatti, R., Gaita, F., Bergerone, S., Bonmassari, R., Zeni, P., Langialonga, T., Scarcia, A., Caravita, L., Musacchio, E., Augello, G., Usmiani, T., Stomaci, B., Cirino, D., Pierini, S., Bottiglieri, G., Liso, A., Mussardo, M., Tosi, P., Sala, R., Belloni, A., Blengino, S., Lisi, E., Delfino, P., Auguadro, C., Brunazzi, M. C., Pacchioni, E., Fattore, L., Bosco, B., Blandizzi, S., Pajes, G., Patruno, N., Perna, G. P., Francioni, M., Favale, S., Vestito, D., Lombardi, A., Capecchi, A., Ferrero, P., De Vincenzo, C., Magri, G., Indolfi, C., De Rosa, S., Rossi, M., Collarini, L., Agnelli, D., Conti, G., Tonelli, C., Spadaro, C., Negroni, S., Di Noto, G., Lanari, A., Casolo, G., Del Meglio, J., Negrini, M., Celentano, A., Sifola, C., Rellini, G., Della Mattia, A., Molero, U., Piovaccari, G., Grosseto, D., Callegarin, L., Fiasconaro, G., Crivello, R., Thiebat, B., Leone, G., Tamburino, C., Caruso, G., Cassadonte, F., Sassone, B., Fuca, G., Sormani, L., Percoco, G. F., Mazzucco, R., Cazzani, E., Gianni, M., Limido, A., Luvini, M., Guglielmi, R., Mannarini, A., Moruzzi, P., Pastori, P., Golia, B., Marzano, A., Orazi, S., Marchese, I., Anselmi, M., Girardi, P., Nassiacos, D., Meloni, S., Busacca, P., Generali, C. A., Corda, S., Costanza, G., Montalto, S., Argenziano, L., Tommasini, P., Emdin, M., Pasanisi, E. M., Colivicchi, F., Tubaro, M., Azzolini, P., Luciani, C., Doronzo, B., Coppolino, A., Dellavesa, P., Zenone, F., Di Marco, A., De Conti, F., Piccinni, G. C., Gualtieri, M. R., Bisignani, G., Leone, A., Arcuri, G. M., Marinacci, L., Rossi, P., Perotti, S., Cotti Cometti, V., Arcidiacono, S., Tramontana, M., Bazzucchi, M., Mezzetti, P., Romano, M., Villani, R., Di Giovambattista, R., Volpe, B., Tedesco, L., Carini, M., Vinci, S., Paolini, E. A., Busoni, F., Piergentili, C., Navazio, A., Manca, F., Cocco, F., Pennetta, C. A., Maggiolini, S., Galbiati, R., Bruna, C., Ferrero, L., Brigido, S., Barducci, E., Musacchio, D., Manduca, B., Marchese, D., Patrassi, L. A., Pattarino, F. A., Rocchi, M., Briglia, S., Fanelli, R., Villella, M., Gronda, E., Massa, D., Lenti, V., Di Gregorio, L., Bottero, M., Bazzanini, F., Braggion, G., Antoniceli, R., Caraceni, D., Guzzo, V., Di Giovanni, P., Scarpini, S., Severgnini, B., Musolino, M. F., Della Casa, S., Gobbi, M., Arena, G., Bonizzato, S., Agnoletto, V., Sansoni, S., Pes, R. A. M., Denti, S., Polizzi, G. M., Pino, R., Commisso, B., Merlino, A., Di Lorenzo, L., Porchetta, I., Del Furia, F., Colombi, E., Covini, D., Cavalieri, F., Antonaci, S., Rubino, G., Ciulla, A., Bui, F., Casorelli, E., Caliendo, L., Laezza, A., Americo, L., Schillaci, A. M., Cordoni, M., Barsotti, L., Gaudio, C., Barilla, F., Cannone, M., Memeo, R., Truncellito, L., Andriani, A., Salituri, S., Verrina, F., Pafi, M., Sebastiani, M. L., Amico, A. F., Scolozzi, D., D'Alea, A., Catanzariti, D., Angheben, C., Ottaviano, A., and Levantesi, G.
- Subjects
Male ,Ticagrelor ,medicine.medical_specialty ,Acute coronary syndrome ,medicine.medical_treatment ,Conservative strategy ,Population ,Acute coronary syndromes ,Revascularization ,acute coronary syndromes ,anticoagulant ,antithrombotic therapy ,conservative strategy ,prasugrel ,ticagrelor ,aged ,coronary care units ,female ,fibrinolytic agents ,follow-up studies ,hospital mortality ,humans ,iItaly ,length of stay ,male ,myocardial revascularization ,retrospective studies ,survival rate ,thrombolytic therapy ,practice guidelines as topic ,Fibrinolytic Agents ,Anticoagulant ,Antithrombotic therapy ,Prasugrel ,Acute Coronary Syndrome ,Aged ,Coronary Care Units ,Female ,Follow-Up Studies ,Hospital Mortality ,Humans ,Italy ,Length of Stay ,Myocardial Revascularization ,Retrospective Studies ,Survival Rate ,Thrombolytic Therapy ,Practice Guidelines as Topic ,Cardiology and Cardiovascular Medicine ,Pharmacology (medical) ,Internal medicine ,Antithrombotic ,medicine ,education ,Survival rate ,education.field_of_study ,business.industry ,Clopidogrel ,medicine.disease ,Cardiology ,business ,Fibrinolytic agent ,medicine.drug - Abstract
Aims Patients with acute coronary syndromes (ACSs) who are managed without coronary revascularization represent a mixed and understudied population that seems to receive suboptimal pharmacological treatment. Methods and results We assessed patterns of antithrombotic therapies employed during the hospitalization and in-hospital clinical events of medically managed patients with ACS enrolled in the prospective, multicentre, nationwide EYESHOT (EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units) registry. Among the 2585 consecutive ACS patients enrolled in EYESHOT, 783 (30.3%) did not receive any revascularization during hospital admission. Of these, 478 (61.0%) underwent coronary angiography (CA), whereas 305 (39.0%) did not. The median GRACE and CRUSADE risk scores were significantly higher among patients who did not undergo CA compared with those who did (180 vs. 145, P < 0.0001 and 50 vs. 33, P < 0.0001, respectively). Antithrombotic therapies employed during hospitalization significantly differ between patients who received CA and those who did not with unfractioned heparin and novel P2Y12 inhibitors more frequently used in the first group, and low-molecular-weight heparins and clopidogrel in the latter group. During the index hospitalization, patients who did not receive CA presented a higher incidence of ischaemic cerebrovascular events and of mortality compared with those who underwent CA (1.6 vs. 0.2%, P = 0.04 and 7.9 vs. 2.7%, P = 0.0009, respectively). Conclusion Almost one-third of ACS patients are managed without revascularization during the index hospitalization. In this population, a lower use of recommended antiplatelet therapy and worse clinical outcome were observed in those who did not undergo CA when compared with those who did. Clinical Trial Registration Unique identifier: [NCT02015624][1], . [10.1093/ehjcvp/pvv017][2] [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02015624&atom=%2Fehjcardpharm%2F1%2F3%2F168.atom [2]: /lookup/doi/10.1093/ehjcvp/pvv017
- Published
- 2015
- Full Text
- View/download PDF
7. Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units Registry
- Author
-
De Luca, L., Musumeci, G., Leonardi, S., Gonzini, L., Cavallini, C., Calabro, P., Mauro, C., Cacciavillani, L., Savonitto, S., De Servi, S., Caporale, R., Ceravolo, R., Formigli, D., Lupi, A., Rakar, S., Smecca, I. M., Maggioni, A. P., Lucci, D., Lorimer, A., Orsini, G., Fabbri, G., Bianchini, E., Abrignani, M. G., Bonura, F., Trimarco, B., Galasso, G., Misuraca, G., Manes, M. T., Tuccillo, B., Irace, L., Olivari, Z., Totis, O., Ledda, A., Boccalatte, M., Iliceto, S., Tortorella, G., Esposito, L., De Rosa, P., Bianchi, R., Napoletano, C., Piccioni, L. L., Pavesi, P. C., Bovenzi, F. M., Boni, A., Merenda, R., Wolff, S., De Ferrari, G. M., Camporotondo, R., Gambino, P., Cutaia, A., Picariello, C., Cemin, R., Chiarella, F., Gauthier, L. G., Mircoli, L., Del Pinto, M., Finocchiaro, M. L., Scioli, R., Farina, R., Naddeo, C., Scherillo, M., Santopietro, S., Metra, M., Costa, F., Calculli, G., Troito, G., Pennisi, V., Adornato, E. M. F., Pirelli, S., Fadin, B. M., DI Biase, M., Ieva, R., Zuin, G., Sanfilippo, N., Mancuso, L., Pani, A., Serra, E., Marenzi, G., Assanelli, E. M., Ansalone, G., Cacciotti, L., Morocutti, G., Fresco, C., Berti, S., Paradossi, U., Bozzano, A., Mauro, A., Noussan, P., Zanini, P., Bolognese, L., Falsini, G., Costa, P., Manca, G., Caldarola, P., Locuratolo, N., Cipolla, T., Becchina, M., Cocco, G., Scalera, G., Stefanelli, S., Giunta, N., Sinagra, G., Meloni, L., Lai, O., Chiaranda, G., Luca, G., Helou, J. S., Biscottini, E., Magliari, F., Callerame, M., Uguccioni, M., Pugliese, M., Sanchez, F., Tartaglione, S., Ignone, G., Mavilio, G., Mantovan, R., Bini, R., Caico, S. I., Demolli, V., Proietti, F., Michisanti, M., Musmeci, G., Cantamessa, P., Sicuso, G., Micalef, S. S., Accogli, M., Zaccaria, M., Caputo, M., DI Paolo, G., Piatti, L., Farina, A., Vicinelli, P., Paloscia, L., DI Clemente, D., Felis, S., Castini, D., Rota, C., Casu, G., Bonano, S., Margheri, M., Lucchi, G. R., Serdoz, R., Proietti, P., Autore, C., Conti, E., Russo, V., Orlando, P., Ramondo, A. B., Bontorin, M., Marcolongo, M., Santagostino, M., Maestroni, A., Vitti, P., Rodella, P., Bonetti, P., Elia, M., Lumare, R., Politi, A., Gritti, S., Poletti, F., Mafrici, A., Fusco, R., Bongo, A. S., Bacchini, S., Gasparetto, V., Ferraiuolo, G., De Luca, M., Campana, C., Bonatti, R., Gaita, F., Bergerone, S., Bonmassari, R., Zeni, P., Langialonga, T., Scarcia, A., Caravita, L., Musacchio, E., Augello, G., Usmiani, T., Stomaci, B., Cirino, D., Pierini, S., Bottiglieri, G., Liso, A., Mussardo, M., Tosi, P., Sala, R., Belloni, A., Blengino, S., Lisi, E., Delfino, P., Auguadro, C., Brunazzi, M. C., Pacchioni, E., Fattore, L., Bosco, B., Blandizzi, S., Pajes, G., Patruno, N., Perna, G. P., Francioni, M., Favale, S., Vestito, D., Lombardi, A., Capecchi, A., Ferrero, P., De Vincenzo, C., Magri, G., Indolfi, C., De Rosa, S., Rossi, M., Collarini, L., Agnelli, D., Conti, G., Tonelli, C., Spadaro, C., Negroni, S., DI Noto, G., Lanari, A., Casolo, G., Del Meglio, J., Negrini, M., Celentano, A., Sifola, C., Rellini, G., Mattia, A. D., Molero, U., Piovaccari, G., Grosseto, D., Callegarin, L., Fiasconaro, G., Crivello, R., Thiebat, B., Leone, G., Tamburino, C., Caruso, G., Cassadonte, F., Sassone, B., Fuca, G., Sormani, L., Percoco, G. F., Mazzucco, R., Cazzani, E., Gianni, M., Limido, A., Luvini, M., Guglielmi, R., Mannarini, A., Moruzzi, P., Pastori, P., Golia, B., Marzano, A., Orazi, S., Marchese, I., Anselmi, M., Girardi, P., Nassiacos, D., Meloni, S., Busacca, P., Generali, C. A., Corda, S., Costanza, G., Montalto, S., Argenziano, L., Tommasini, P., Emdin, M., Pasanisi, E. M., Colivicchi, F., Tubaro, M., Azzolini, P., Luciani, C., Doronzo, B., Coppolino, A., Dellavesa, P., Zenone, F., DI Marco, A., De Conti, F., Piccinni, G. C., Gualtieri, M. R., Bisignani, G., Leone, A., Arcuri, G. M., Marinacci, L., Rossi, P., Perotti, S., Cometti, V. C., Arcidiacono, S., Tramontana, M., Bazzucchi, M., Mezzetti, P., Romano, M., Villani, R., DI Giovambattista, R., Volpe, B., Tedesco, L., Carini, M., Vinci, S., Paolini, E. A., Busoni, F., Piergentili, C., Navazio, A., Manca, F., Cocco, F., Pennetta, C. A., Maggiolini, S., Galbiati, R., Bruna, C., Ferrero, L., Brigido, S., Barducci, E., Musacchio, D., Manduca, B., Marchese, D., Patrassi, L. A., Pattarino, F. A., Rocchi, M., Briglia, S., Fanelli, R., Villella, M., Gronda, E., Massa, D., Lenti, V., DI Gregorio, L., Bottero, M., Bazzanini, F., Braggion, G., Antoniceli, R., Caraceni, D., Guzzo, V., DI Giovanni, P., Scarpini, S., Severgnini, B., Musolino, M. F., Casa, S. D., Gobbi, M., Arena, G., Bonizzato, S., Agnoletto, V., Sansoni, S., Pes, R. A. M., Denti, S., Polizzi, G. M., Pino, R., Commisso, B., Merlino, A., DI Lorenzo, L., Porchetta, I., Del Furia, F., Colombi, E., Covini, D., Cavalieri, F., Antonaci, S., Rubino, G., Ciulla, A., Bui, F., Casorelli, E., Caliendo, L., Laezza, A., Americo, L., Schillaci, A. M., Cordoni, M., Barsotti, L., Gaudio, C., Barilla, F., Cannone, M., Memeo, R., Truncellito, L., Andriani, A., Salituri, S., Verrina, F., Pafi, M., Sebastiani, M. L., Amico, A. F., Scolozzi, D., Lupi, G., D'Alea, A., Catanzariti, D., Angheben, C., Ottaviano, A., Levantesi, G., de Luca, Leonardo, Musumeci, Giuseppe, Leonardi, Sergio, Gonzini, Lucio, Cavallini, Claudio, Calabrò, Paolo, Mauro, Ciro, Cacciavillani, Luisa, Savonitto, Stefano, de Servi, Stefano, Caporale, Roberto, Ceravolo, Roberto, Formigli, Dario, Lupi, Alessandro, Rakar, Sadir, Smecca, Ivan, Maggioni, Aldo Pietro, Lucci, Donata, Lorimer, Andrea, Orsini, Giampietro, Fabbri, Gianna, Bianchini, Elisa, Abrignani, Maurizio Giuseppe, Bonura, Francesc, Trimarco, Bruno, Galasso, Gennaro, Misuraca, Gianfranco, Manes, Maria Teresa, Tuccillo, Bernardino, and Irace, Luigi.
- Subjects
Male ,Prasugrel ,medicine.medical_treatment ,Myocardial Infarction ,antithrombotic therapy ,030204 cardiovascular system & hematology ,acute coronary syndromes ,bivalirudin ,heparins ,percutaneous coronary intervention ,prasugrel ,ticagrelor ,0302 clinical medicine ,Antithrombotic ,80 and over ,Bivalirudin ,030212 general & internal medicine ,Myocardial infarction ,Prospective Studies ,Registries ,Aged, 80 and over ,General Medicine ,Hirudins ,Middle Aged ,Recombinant Proteins ,Italy ,Female ,Cardiology and Cardiovascular Medicine ,Ticagrelor ,medicine.drug ,medicine.medical_specialty ,Platelet Glycoprotein GPIIb-IIIa Complex ,NO ,03 medical and health sciences ,Percutaneous Coronary Intervention ,Internal medicine ,medicine ,Humans ,Acute Coronary Syndrome ,Aged ,Aspirin ,business.industry ,Heparin ,Percutaneous coronary intervention ,Anticoagulants ,medicine.disease ,Peptide Fragments ,Clinical trial ,Cross-Sectional Studies ,Logistic Models ,Conventional PCI ,Multivariate Analysis ,business - Abstract
Aims In the last decades, several new therapies have emerged for the treatment of acute coronary syndromes (ACS). We sought to describe real-world patterns of use of antithrombotic treatments in the catheterization laboratory for ACS patients undergoing percutaneous coronary interventions (PCI). Methods EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units was a nationwide, prospective registry aimed to evaluate antithrombotic strategies employed in ACS patients in Italy. Results Over a 3-week period, a total of 2585 consecutive ACS patients have been enrolled in 203 cardiac care units across Italy. Among these patients, 1755 underwent PCI (923 with ST-elevation myocardial infarction and 832 with non-ST-elevation ACS). In the catheterization laboratory, unfractioned heparin was the most used antithrombotic drug in both ST-elevation myocardial infarction (64.7%) and non-ST-elevation ACS (77.5%) undergoing PCI and, as aspirin, bivalirudin and glycoprotein IIb/IIIa inhibitors (GPIs) more frequently employed before or during PCI compared with the postprocedural period. Any crossover of heparin therapy occurred in 36.0% of cases, whereas switching from one P2Y12 inhibitor to another occurred in 3.7% of patients. Multivariable analysis yielded several independent predictors of GPIs and of bivalirudin use in the catheterization laboratory, mainly related to clinical presentation, PCI complexity and presence of complications during the procedure. Conclusion In our contemporary, nationwide, all-comers cohort of ACS patients undergoing PCI, antithrombotic therapies were commonly initiated before the catheterization laboratory. In the periprocedural period, the most frequently employed drugs were unfractioned heparin, leading to a high rate of crossover, followed by GPIs and bivalirudin, mainly used during complex PCI. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02015624.
- Published
- 2017
8. COMMD7 as a novel NEMO interacting protein involved in the termination of NF-kB signaling
- Author
-
Esposito E, Napolitano G, Pescatore A, Calculli G, Incoronato MR, Leonardi A, and Ursini MV.
- Subjects
NEMO/IKK? ,skin and connective tissue diseases - Abstract
NEMO/IKK? is the regulatory subunit of the I?B Kinase (IKK) complex, required for the activation of the NF-?B pathway, which is involved in a variety of key processes, including immunity, inflammation, differentiation, and cell survival. Termination of NF-?B activity on specific -?B responsive genes, which is crucial for the resolution of inflammatory responses, can be achieved by direct degradation of the chromatin-bound NF-?B subunit RelA/p65, a process mediated by a protein complex that contains Copper Metabolism Murr1 Domain 1 (COMMD1). In this study, we identify COMMD7, another member of the COMMDs protein family, as a novel NEMO-interacting protein. We show that COMMD7 exerts an inhibitory effect on NF-?B activation upon TNF? stimulation. COMMD7 interacts with COMMD1 and together they cooperate to down-regulate NF-?B activity. Accordingly, termination of TNF?-induced NF-?B activity on the -?B responsive gene, Icam1, is defective in cells silenced for COMMD7 expression. Furthermore, this impairment is not greatly increased when we silence the expression of both COMMD7 and COMMD1 indicating that the two proteins participate in the same pathway of termination of TNF?-induced NF-?B activity. Importantly, we have demonstrated that COMMD7's binding to NEMO does not interfere with the binding to the IKKs, and that the disruption of the IKK complex through the use of the NBP competitor impairs the termination of NF-?B activity. We propose that an intact IKK complex is required for the termination of NF-?B-dependent transcription and that COMMD7 acts as a scaffold in the IKK-mediated NF-?B termination.
- Published
- 2016
- Full Text
- View/download PDF
9. A remote sensing approach in a marine coastal zone: Gulf of Manfredonia.
- Author
-
Veneziani, N., Calculli, G., Spagnoli, F., and Decembrini, F.
- Published
- 2005
- Full Text
- View/download PDF
10. Treatment of isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. Associazione Italiana Ematologia ed Oncologia Pediatrica.
- Author
-
Uderzo, C, primary, Grazia Zurlo, M, additional, Adamoli, L, additional, Zanesco, L, additional, Aricò, M, additional, Calculli, G, additional, Comelli, A, additional, Cordero di Montezemolo, L, additional, Di Tullio, M T, additional, and Guazzelli, C, additional
- Published
- 1990
- Full Text
- View/download PDF
11. Circulating Immune Complexes in Human Acute Leukaemia.
- Author
-
Balestrieri, G., Tincani, Angela, Cattaneo, R., Rossi, G., Verzura, Paola, Marini, G., Calculli, G., Ferremi, P., and Marinone, G.
- Published
- 1981
- Full Text
- View/download PDF
12. Health status of young children with cancer following discontinuation of therapy.
- Author
-
Pastore, G., Zurlo, M. G., Acquaviva, A., Calculli, G., Castello, M., Ceci, A., Di Tullio, M. L., Gandus, S., Macchia, P., Di Montezemolo, L. Cordero, Mandelli, F., Massolo, F., Nespoli, L., Paolucci, G., Rosate, M., Senesi, E., Tamaro, P., Tripoli, U., and Terracini, B.
- Published
- 1987
- Full Text
- View/download PDF
13. Health status of disease-free long-term survivors after childhood acute lymphoblastic leukemia
- Author
-
Senesi, E, Adamoli, L, Calculli, G, Casa, F, Casale, F, CORDERO DI MONTEZEMOLO, Luca, Garrè, Ml, Massolo, F, Mazzoleni, E, and Miccolis, S.
- Subjects
Adult ,Male ,Adolescent ,Health ,Child, Preschool ,Health Status ,Infant, Newborn ,Humans ,Infant ,Female ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Child - Published
- 1988
14. Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group
- Author
-
Carli, Modesto Ottaviano, GIORGIO PERILONGO, di Montezemolo LC, Bernardi, B., Ceci, A., Paolucci, G., Pianca, C., Calculli, G., Di Tullio MT, and Grotto, P.
- Subjects
Adolescent ,Child, Preschool ,Antineoplastic Combined Chemotherapy Protocols ,Rhabdomyosarcoma ,CHEMOTHERAPY ,Drug Evaluation ,Humans ,Sarcoma ,Soft Tissue Neoplasms ,Cisplatin ,Child ,Etoposide - Abstract
A phase II multicenter evaluation of cisplatin (90 mg/m2, Day 1) and etoposide (150 mg/m2, Days 2, 3, and 4) in 4-week cycles was carried out in 21 relapsed children with rhabdomyosarcoma (RMS) and six with non-RMS soft tissue sarcomas (NRSTS). Clinical responses were evaluated after four cycles. There were three complete responses (CRs) and four partial responses (PRs) among the 21 patients with RMS and no responses among the patients with NRSTS. The durations of the three CRs and the four PRs were 11, 9, and 8 months, and 5, 2, 2, and 1 month, respectively. Bone marrow and renal toxicity was cumulative and predictable, but not life threatening. The response rate (CR + PR = 33.3%) to cisplatin and etoposide warrants testing as front-line therapy for RMS.
- Published
- 1987
15. Phase II trial of amsacrine in children with advanced metastatic neuroblastoma
- Author
-
Bernardi, B., Pastore, G., ALBERTO GARAVENTA, Calculli, G., Carli, M., Ceci, A., Di Montezemolo, L. C., Pianca, C., Romano, C., and Russo, A.
- Subjects
Amsacrine ,Male ,Neuroblastoma ,Aminoacridines ,Child, Preschool ,Drug Evaluation ,Humans ,Infant ,Antineoplastic Agents ,Female ,Child - Published
- 1984
16. Il fenotipo immunologico della Leucemia linfoblastica Acuta (LLA): protocolli AIEOP_LLA 1976-79-82-85-87
- Author
-
Basso, G, Paolucci, P, Putti, Mc, Calculli, G, Lippi, A, Cantù, Rajnoldi, Comelli, A, A, and Consolini, Rita
- Published
- 1988
17. In vivo studies with I 131 Tetraiodo Benzylguanidine in neuroblastoma: Preliminary report
- Author
-
Bestagno, M, Guerra, Up, Terzi, A, Pagliaini, R, Maira, G, Giubbini, Raffaele, Calculli, G, and Ekema, G.
- Published
- 1985
18. Treatment of neuroblastoma with 131I‐metaiodobenzylguanidine: The experience of an Italian study group
- Author
-
Bestagno, M., primary, Guerra, P., additional, Puricelli, G. P., additional, Colombo, L., additional, and Calculli, G., additional
- Published
- 1987
- Full Text
- View/download PDF
19. A remote sensing approach in a marine coastal zone: Gulf of Manfredonia
- Author
-
Veneziani, N., primary, Calculli, G., additional, Spagnoli, F., additional, and Decembrini, F., additional
- Full Text
- View/download PDF
20. Treatment of neuroblastoma with 131I-metaiodobenzylguanidine: The experience of an Italian study group.
- Author
-
Bestagno, M., Guerra, P., Puricelli, G. P., Colombo, L., and Calculli, G.
- Published
- 1987
- Full Text
- View/download PDF
21. Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review and presentation and insights on pathogenesis of synchronous sporadic mesenteric desmoid tumors occurring after surgery for necrotizing pancreatitis.
- Author
-
Prete F, Rotelli M, Stella A, Calculli G, Sgaramella LI, Amati A, Resta N, Testini M, and Gurrado A
- Subjects
- Male, Humans, Middle Aged, Mutation, Inflammation complications, beta Catenin genetics, Fibromatosis, Aggressive genetics, Fibromatosis, Aggressive surgery, Fibromatosis, Aggressive diagnosis, Pancreatitis complications, MicroRNAs genetics
- Abstract
Sporadic intra-abdominal desmoid tumors are rare and known to potentially occur after trauma including previous surgery, although knowledge of the underlying pathogenetic mechanism is still limited. We reviewed the recent literature on sporadic intraabdominal desmoids and inflammation as we investigated the mutational and epigenetic makeup of a case of multiple synchronous mesenterial desmoids occurring after necrotizing pancreatitis. A 62-year-old man had four mesenteric masses up to 4.8 cm diameter detected on CT eighteen months after laparotomy for peripancreatic collections from necrotizing pancreatitis. All tumors were excised and diagnosed as mesenteric desmoids. DNA from peripheral blood was tested for a multigene panel. The tumour DNA was screened for three most frequent β-catenin gene mutations T41A, S45F and S45P. Expression levels of miR-21-3p and miR-197-3-p were compared between the desmoid tumors and other wild-type sporadic desmoids. The T41A CTNNB1 mutation was present in all four desmoid tumors. miR-21-3p and miR-197-3p were respectively upregulated and down-regulated in the mutated sporadic mesenteric desmoids, with respect to wild-type lesions. The patient is free from recurrence 34 months post-surgery. The literature review did not show similar studies. To our knowledge, this is the first study to interrogate genetic and epigenetic signature of multiple intraabdominal desmoids to investigate potential association with abdominal inflammation following surgery for necrotizing pancreatitis. We found mutational and epigenetic features that hint at potential activation of inflammation pathways within the desmoid tumor., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
22. Introducing routine intraoperative nerve monitoring in a high-volume endocrine surgery centre: a health technology assessment.
- Author
-
Prete FP, Sgaramella LI, Di Meo G, Pasculli A, Calculli G, Protopapa G, Gurrado A, and Testini M
- Subjects
- Humans, Recurrent Laryngeal Nerve, Retrospective Studies, Technology Assessment, Biomedical, Thyroidectomy, Recurrent Laryngeal Nerve Injuries prevention & control, Vocal Cord Paralysis
- Abstract
We sought to analyse the effect of the introduction of intraoperative nerve monitoring (IONM) in our routine surgical practice and to provide a circumstantial analysis of direct costs of IONM in total thyroidectomy and of indirect costs associated with vocal fold palsy, as centred in the health care system of Italy. We retrospectively compared outcomes of 232 total thyroidectomies performed between November 2017 and October 2019, respectively, before (109 TT-Group A) and after (123 TT-Group B) adopting IONM technology in November 2018. We analysed the costs of IONM per procedure and rate and costs of vocal fold palsy events (temporary and permanent). Overall, there were 61 thyroid cancers (32 in Group B) and 171 multinodular goitres (91 in Group B). We recorded 5 cases of vocal fold palsy (4.6%-4 transient, 1 permanent) in Group A and none in Group B (p = 0.016). IONM consumables cost 219 eur per case. Healthcare and social cost of Vocal fold palsy ranged between 3200 eur (function recovery < 1 month postoperatively) and over 32,000 eur (permanent event). When only direct costs are considered, IONM can hardly be cost effective. In this study, cost of IONM implementation was offset by the absence of complications attributable to recurrent laryngeal nerve dysfunction., (© 2021. Italian Society of Surgery (SIC).)
- Published
- 2021
- Full Text
- View/download PDF
23. Systemic regulation of mitochondria by germline proteostasis prevents protein aggregation in the soma of C. elegans .
- Author
-
Calculli G, Lee HJ, Shen K, Pham U, Herholz M, Trifunovic A, Dillin A, and Vilchez D
- Abstract
Protein aggregation causes intracellular changes in neurons, which elicit signals to modulate proteostasis in the periphery. Beyond the nervous system, a fundamental question is whether other organs also communicate their proteostasis status to distal tissues. Here, we examine whether proteostasis of the germ line influences somatic tissues. To this end, we induce aggregation of germline-specific PGL-1 protein in germline stem cells of Caenorhabditis elegans Besides altering the intracellular mitochondrial network of germline cells, PGL-1 aggregation also reduces the mitochondrial content of somatic tissues through long-range Wnt signaling pathway. This process induces the unfolded protein response of the mitochondria in the soma, promoting somatic mitochondrial fragmentation and aggregation of proteins linked with neurodegenerative diseases such as Huntington's and amyotrophic lateral sclerosis. Thus, the proteostasis status of germline stem cells coordinates mitochondrial networks and protein aggregation through the organism., (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).)
- Published
- 2021
- Full Text
- View/download PDF
24. [Twiddler's syndrome: a rare but possible cause of cardiac resynchronization therapy-defibrillator malfunction].
- Author
-
Cortese F, Dachille A, Bochicchio A, Clemente M, Truncellito L, Calculli G, and Andriani A
- Subjects
- Equipment Failure, Humans, Syndrome, Cardiac Resynchronization Therapy, Defibrillators, Implantable adverse effects, Pacemaker, Artificial
- Published
- 2021
- Full Text
- View/download PDF
25. The Value of Intraoperative Ultrasound in Selective Lateral Cervical Neck Lymphadenectomy for Papillary Thyroid Cancer: A Prospective Pilot Study.
- Author
-
Di Meo G, Prete FP, De Luca GM, Pasculli A, Sgaramella LI, Minerva F, Logoluso FA, Calculli G, Gurrado A, and Testini M
- Abstract
(1) Background: Lymph node metastases from papillary thyroid cancer (PTC) are frequent. Selective neck dissection (SND) is indicated in PTC with clinical or imaging evidence of lateral neck nodal disease. Both preoperative ultrasound (PreUS) and intraoperative palpation or visualization may underestimate actual lateral neck nodal involvement, particularly for lymph-nodes located behind the sternocleidomastoid muscle, where dissection may also potentially increase the risk of postoperative complications. The significance of diagnostic IOUS in metastatic PTC is under-investigated. (2) Methods: We designed a prospective diagnostic study to assess the diagnostic accuracy of IOUS compared to PreUS in detecting metastatic lateral neck lymph nodes from PTC during SND. (3) Results: There were 33 patients with preoperative evidence of lateral neck nodal involvement from PTC based on PreUS and fine-needle cytology. In these patients, IOUS guided the excision of additional nodal compartments that were not predicted by PreUS in nine (27.2%) cases, of which eight (24.2%) proved to harbor positive nodes at pathology. The detection of levels IIb and V increased, respectively, from 9% (PreUS) to 21% (IOUS) ( p < 0.0001) and from 15% to 24% ( p = 0.006). (4) Conclusions: In the context of this study, IOUS showed higher sensitivity and specificity than PreUS scans in detecting metastatic lateral cervical nodes. This study showed that IOUS may enable precise SND to achieve oncological radicality, limiting postoperative morbidity.
- Published
- 2021
- Full Text
- View/download PDF
26. The electrocardiographic changes associated with hypothermia: the Osborn wave.
- Author
-
Cortese F, Paglia A, Contuzzi R, Andriani A, Truncellito L, and Calculli G
- Subjects
- Aged, 80 and over, Humans, Male, Electrocardiography, Hypothermia diagnosis
- Published
- 2020
- Full Text
- View/download PDF
27. Uric Acid in Metabolic and Cerebrovascular Disorders: A Review.
- Author
-
Cortese F, Scicchitano P, Cortese AM, Meliota G, Andriani A, Truncellito L, Calculli G, Giordano P, and Ciccone MM
- Subjects
- Animals, Biomarkers blood, Cardiometabolic Risk Factors, Cerebrovascular Disorders etiology, Cerebrovascular Disorders physiopathology, Diabetes Mellitus, Type 2 etiology, Diabetes Mellitus, Type 2 physiopathology, Humans, Hyperuricemia complications, Metabolic Syndrome etiology, Metabolic Syndrome physiopathology, Prognosis, Risk Assessment, Blood Glucose metabolism, Cerebrovascular Disorders blood, Diabetes Mellitus, Type 2 blood, Hyperuricemia blood, Metabolic Syndrome blood, Uric Acid blood
- Abstract
Background: Several studies showed a close link between metabolic syndrome (MetS), type 2 diabetes (T2DM) and cerebrovascular diseases. There is considerable debate regarding the role of uric acid (UA) as a risk factor in these conditions., Objective: The aim of this narrative review is to discuss the links between UA, MetS, T2DM and cerebrovascular disease., Methods: An extensive review has been conducted based on the scientific literature published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and Google Scholar from January to May 2019. Additional relevant studies published after the initial review were also considered during the period of June 2019-October 2019, during which, this manuscript was written. The Mesh Terms considered were: uric acid, antioxidant, oxidant, metabolic syndrome, diabetes, cerebrovascular diseases, stroke, haemorrhagic stroke, neurocognitive disorders, and their combinations., Results: The literature review shows a dose-dependent inflammatory action of UA, which occurs with serum concentrations >4 mg/dl (>0.24 mmol/l), representing one of the contributors to the chronic inflammatory process that underlies metabolic and cerebrovascular diseases., Conclusion: UA, which is associated with arterial hypertension and cardiovascular diseases, represents one of the indicators of oxidative homeostasis. Increasing concentrations represent a status of active inflammation which is observed with metabolic and cerebrovascular diseases., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2020
- Full Text
- View/download PDF
28. Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects.
- Author
-
Cortese F, Giordano P, Scicchitano P, Faienza MF, De Pergola G, Calculli G, Meliota G, and Ciccone MM
- Subjects
- Animals, Biomarkers blood, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Gout Suppressants therapeutic use, Humans, Hyperuricemia diagnosis, Hyperuricemia epidemiology, Hyperuricemia therapy, Mutation, Risk Factors, Risk Reduction Behavior, Urate Oxidase genetics, Urate Oxidase metabolism, Cardiovascular Diseases blood, Hyperuricemia blood, Uric Acid blood
- Abstract
Non-communicable diseases represent nowadays the most common cause of death worldwide, having largely overcome infectious diseases. Among them, cardiovascular diseases constitute the majority. Given these premise, great efforts have been made by scientific societies to emphasize the fundamental role of cardiovascular prevention and risk factors control. In addition to classical cardiovascular risk factors such as smoking, arterial hypertension, hypercholesterolemia and male gender, new risk factors are emerging from international literature. Among them, uric acid is the protagonist. Several evidences show a direct role of hyperuricemia in the determinism of metabolic and vascular disorders. From the other hand, some researchers have demonstrated that uric acid is only a marker of cardiovascular damage and not a risk factor for its development. Aim of this review is to evaluate the scientific evidences on the role of uric acid in cardiovascular diseases in order to shed light on this confusing topic., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
29. Prostaglandin signals from adult germ stem cells delay somatic aging of Caenorhabditis elegans .
- Author
-
Lee HJ, Noormohammadi A, Koyuncu S, Calculli G, Simic MS, Herholz M, Trifunovic A, and Vilchez D
- Subjects
- Animals, Caenorhabditis elegans physiology, Longevity physiology, Prostaglandins metabolism, Signal Transduction, Stem Cells metabolism
- Abstract
A moderate reduction of body temperature can induce a remarkable lifespan extension. Here we examine the link between cold temperature, germ line fitness and organismal longevity. We show that low temperature reduces age-associated exhaustion of germ stem cells (GSCs) in Caenorhabditis elegans , a process modulated by thermosensory neurons. Notably, robust self-renewal of adult GSCs delays reproductive aging and is required for extended lifespan at cold temperatures. These cells release prostaglandin E2 (PGE2) to induce cbs-1 expression in the intestine, increasing somatic production of hydrogen sulfide (H
2 S), a gaseous signaling molecule that prolongs lifespan. Whereas loss of adult GSCs reduces intestinal cbs-1 expression and cold-induced longevity, application of exogenous PGE2 rescues these phenotypes. Importantly, tissue-specific intestinal overexpression of cbs-1 mimics cold-temperature conditions and extends longevity even at warm temperatures. Thus, our results indicate that GSCs communicate with somatic tissues to coordinate extended reproductive capacity with longevity., Competing Interests: Competing interests The authors declare no competing interests.- Published
- 2019
- Full Text
- View/download PDF
30. [Electrocardiographic changes associated with cardiac metastasis].
- Author
-
Cortese F, Di Marino S, Portulano V, Scicchitano P, Ciccone MM, and Calculli G
- Subjects
- Aged, 80 and over, Female, Humans, Electrocardiography, Heart Neoplasms physiopathology, Heart Neoplasms secondary
- Published
- 2019
- Full Text
- View/download PDF
31. [Giant negative T waves on the electrocardiogram: what is underneath?]
- Author
-
Cortese F, Giordano P, Ciccone MM, and Calculli G
- Subjects
- Adult, Humans, Male, Arrhythmias, Cardiac diagnosis, Electrocardiography
- Published
- 2019
- Full Text
- View/download PDF
32. A perforated cardiac pseudoaneurysm complicating an acute myocardial infarction.
- Author
-
Cortese F, Costantino MF, Ciccone MM, and Calculli G
- Subjects
- Aneurysm, False etiology, Aneurysm, False surgery, Aneurysm, Ruptured etiology, Aneurysm, Ruptured surgery, Echocardiography, Doppler, Heart Aneurysm etiology, Heart Aneurysm surgery, Heart Ventricles diagnostic imaging, Heart Ventricles surgery, Humans, Magnetic Resonance Imaging, Aneurysm, False diagnostic imaging, Aneurysm, Ruptured diagnostic imaging, Heart Aneurysm diagnostic imaging, ST Elevation Myocardial Infarction complications
- Published
- 2018
- Full Text
- View/download PDF
33. A percutaneous repair of a coronary pseudo-aneurysm, the role of the intravascular ultrasound.
- Author
-
Calculli G, Contuzzi R, Ciccone MM, Loiodice C, and Cortese F
- Subjects
- Aged, Aneurysm, False diagnosis, Coronary Aneurysm diagnosis, Coronary Angiography, Coronary Vessels diagnostic imaging, Humans, Male, Aneurysm, False surgery, Coronary Aneurysm surgery, Coronary Vessels surgery, Percutaneous Coronary Intervention methods, Ultrasonography, Interventional methods
- Published
- 2018
- Full Text
- View/download PDF
34. Idarucizumab: What Should We Know?
- Author
-
Cortese F, Calculli G, Gesualdo M, Cecere A, Zito A, De Vito F, Carbonara R, Carbonara S, Cortese AM, and Ciccone MM
- Subjects
- Animals, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized pharmacokinetics, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Antibodies, Monoclonal, Humanized pharmacology, Antithrombins adverse effects, Dabigatran adverse effects, Hemorrhage prevention & control
- Abstract
Background: Idarucizumab, a humanized monoclonal antibody fragment acting as a specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure haemostasis. Moreover, it can also be applied to reverse the dabigatran anticoagulant activity in emergency surgery or in other invasive procedure at high risk of bleeding., Objective: In this study, we discuss idarucizumab in light of the available literature data by conducting extensive research in the PubMed, EMBASE and Cochrane Library on the topic, using idarucizumab, dabigatran and their combinations as Mesh terms, and focusing on high impact investigations., Results: Several studies have demonstrated the capacity of idarucizumab to reverse laboratory measures of dabigatran-associated coagulopathy, however its efficacy and safety in real world patients are still not very clear because of the scarcity of available data which should be assessed with an extensive post market surveillance., Conclusion: The introduction of idarucizumab as dabigatran antidote in clinical practice represents a useful tool for clinicians. The possibility to rapidly restore the anticoagulation activity of dabigatran makes its use simpler and more manageable., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
- Published
- 2018
- Full Text
- View/download PDF
35. Mechanisms of protein homeostasis (proteostasis) maintain stem cell identity in mammalian pluripotent stem cells.
- Author
-
Noormohammadi A, Calculli G, Gutierrez-Garcia R, Khodakarami A, Koyuncu S, and Vilchez D
- Subjects
- Animals, Cell Differentiation, Cell Survival, Humans, Models, Biological, Pluripotent Stem Cells cytology, Unfolded Protein Response, Endoplasmic Reticulum Stress, Pluripotent Stem Cells metabolism, Proteome metabolism, Proteostasis
- Abstract
Protein homeostasis, or proteostasis, is essential for cell function, development, and organismal viability. The composition of the proteome is adjusted to the specific requirements of a particular cell type and status. Moreover, multiple metabolic and environmental conditions challenge the integrity of the proteome. To maintain the quality of the proteome, the proteostasis network monitors proteins from their synthesis through their degradation. Whereas somatic stem cells lose their ability to maintain proteostasis with age, immortal pluripotent stem cells exhibit a stringent proteostasis network associated with their biological function and intrinsic characteristics. Moreover, growing evidence indicates that enhanced proteostasis mechanisms play a central role in immortality and cell fate decisions of pluripotent stem cells. Here, we will review new insights into the melding fields of proteostasis and pluripotency and their implications for the understanding of organismal development and survival.
- Published
- 2018
- Full Text
- View/download PDF
36. Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group.
- Author
-
Carli M, Perilongo G, di Montezemolo LC, De Bernardi B, Ceci A, Paolucci G, Pianca C, Calculli G, Di Tullio MT, and Grotto P
- Subjects
- Adolescent, Child, Child, Preschool, Cisplatin administration & dosage, Cisplatin adverse effects, Drug Evaluation, Etoposide administration & dosage, Etoposide adverse effects, Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Rhabdomyosarcoma drug therapy, Sarcoma drug therapy, Soft Tissue Neoplasms drug therapy
- Abstract
A phase II multicenter evaluation of cisplatin (90 mg/m2, Day 1) and etoposide (150 mg/m2, Days 2, 3, and 4) in 4-week cycles was carried out in 21 relapsed children with rhabdomyosarcoma (RMS) and six with non-RMS soft tissue sarcomas (NRSTS). Clinical responses were evaluated after four cycles. There were three complete responses (CRs) and four partial responses (PRs) among the 21 patients with RMS and no responses among the patients with NRSTS. The durations of the three CRs and the four PRs were 11, 9, and 8 months, and 5, 2, 2, and 1 month, respectively. Bone marrow and renal toxicity was cumulative and predictable, but not life threatening. The response rate (CR + PR = 33.3%) to cisplatin and etoposide warrants testing as front-line therapy for RMS.
- Published
- 1987
37. Heterogeneity of immunological patterns in Langerhan's histiocytosis and response to crude calf thymic extract in 11 patients.
- Author
-
Ceci A, de Terlizzi M, Toma MG, Calculli G, Caputo R, Castello M, Indolfi P, and Rosati D
- Subjects
- Child, Child, Preschool, Histiocytosis, Langerhans-Cell drug therapy, Humans, Infant, Phenotype, T-Lymphocytes classification, T-Lymphocytes immunology, Histiocytosis, Langerhans-Cell immunology, Thymus Extracts therapeutic use
- Abstract
Response to treatment with daily intramuscularly administered crude calf thymic extract (Suppressin) in 11 patients with Langerhan's histiocytosis (L.H.) is reported. In ten patients, T-lymphocytic subsets were studied before starting immunotherapy: OKT3 positive and OKT4 positive cells were reduced in four patients; OKT8 positive cells were reduced in two patients; three patients were normal. After immunotherapy, one patient entered complete remission, four patients had stationary disease, and six had marked clinical progression. Subsequently eight patients underwent conventional chemotherapy, and only three entered complete remission. This study has demonstrated the heterogeneity of immunological patterns in L.H. and justifies the necessity for investigations on the immunoregulatory mechanism of L.H.
- Published
- 1988
- Full Text
- View/download PDF
38. [Leukemic ophthalmopathy: results of a retrospective analysis by the Italian Pediatric Group for the Study of Acute Leukemia].
- Author
-
Lo Curto M, La Grutta S, Schifano V, Acquaviva A, Calculli G, Bagnulo S, Dini G, Di Tullio MT, Donfrancesco A, and Guazzelli C
- Subjects
- Adolescent, Child, Child, Preschool, Eye Diseases pathology, Eye Diseases therapy, Female, Humans, Infant, Leukemia, Lymphoid complications, Male, Retrospective Studies, Time Factors, Eye Diseases etiology, Leukemia complications
- Published
- 1985
39. IV-S neuroblastoma: a cooperative study of 30 children.
- Author
-
Mancini AF, Rosito P, Vitelli A, Paolucci P, Vecchi V, Paolucci G, de Bernardi B, Calculli G, Carli M, and Castello M
- Subjects
- Adrenal Gland Neoplasms diagnosis, Age Factors, Female, Head and Neck Neoplasms diagnosis, Humans, Infant, Infant, Newborn, Liver Neoplasms secondary, Male, Neoplasm Metastasis, Neuroblastoma mortality, Neuroblastoma therapy, Prognosis, Retrospective Studies, Neuroblastoma diagnosis
- Abstract
The clinical features of 30 children with IV-S neuroblastoma have been reviewed. They were treated at 11 Italian pediatric institutions in the period 1970-1981. Patients with IV-S neuroblastoma comprise 6.1% of all the neuroblastoma cases observed during that period. The age at diagnosis ranged from birth to 11 months (mean, 3 months). The distribution of "primary" lesions was of interest. The adrenal gland was affected most often (57% of patients), but tumors of the chest and neck were also encountered. No specific "primary" lesion was identified in ten children. The most frequent site of widespread disease was the liver (87%). Neither the size of the "primary" tumor, nor the number or size of subcutaneous nodules was of prognostic significance. Unfavorable features were age less than 2 months and clinical signs of pulmonary, renal, or hepatic embarrassment. These data confirm the need for prompt intervention in the infant who is suffering from compression of these vital structures by the enlarged liver. Radiation therapy is to be preferred for this purpose, because of the often severe toxicity that is associated with chemotherapy in infants. One, and possibly two babies in this series died of chemotherapy-related complications.
- Published
- 1984
- Full Text
- View/download PDF
40. Phase II trial of amsacrine in children with advanced metastatic neuroblastoma.
- Author
-
De Bernardi B, Pastore G, Garaventa A, Calculli G, Carli M, Ceci A, di Montezemolo LC, Pianca C, Romano C, and Russo A
- Subjects
- Aminoacridines adverse effects, Amsacrine, Child, Child, Preschool, Drug Evaluation, Female, Humans, Infant, Male, Neuroblastoma secondary, Aminoacridines therapeutic use, Antineoplastic Agents therapeutic use, Neuroblastoma drug therapy
- Published
- 1984
41. Early deaths in acute lymphoblastic leukemia (ALL): results of the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (AIL-AIEOP).
- Author
-
Dini G, Bartolini M, Massimo L, Ceci A, Paolucci G, Calculli G, Russo A, Magro S, Guazzelli C, and Cesana BM
- Subjects
- Adolescent, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Heart Diseases mortality, Hemorrhage mortality, Humans, Infant, Infections mortality, Kidney Diseases mortality, Leukemia, Lymphoid drug therapy, Leukemia, Lymphoid pathology, Mediastinal Neoplasms mortality, Prognosis, Retrospective Studies, Leukemia, Lymphoid mortality
- Abstract
In this retrospective multicentric study, we report on early deaths (ie, those that occurred during the first month of treatment) in a total of 943 newly diagnosed ALL pediatric patients registered from 1976 to 1981 at 21 centers of the AIL- AIEOP . Objectives of this study were as follows: (1) to verify the incidence and the cause of early death in a wide population of children with ALL and (2) to elucidate factors associated with early death and therefore to identify "high-risk" groups of patients. Out of the 943 ALL patients, 39 (4.1%) early deaths were registered. Main causes were infection, 20 patients (51.3%); hemorrhage, 11 patients (28.3%); uric acid nephropathy, 2 patients (5.1%); cardiac failure, 3 patients (7.6%); syndrome of inappropriate antidiuretic hormone secretion, 1 patient. Two patients died during the first week of unknown cause. Thirteen factors measured at diagnosis and possibly influencing the early death rate were analyzed. Using the chi-square test, only three of these factors (age, mediastinum status, surface markers) appear to have any significant influence on the early death rate. We also tried to determine how therapy influences this process by analyzing variations in the early death rate, other factors being equal. Significant differences in the early death rates were encountered in AIEOP protocols using different induction regimens.
- Published
- 1984
- Full Text
- View/download PDF
42. Combined therapy for malignant brain tumors in children.
- Author
-
Knerich R, Adinolfi D, Buoncristiani P, Butti G, Calculli G, Cordero di Montezemolo L, Madon E, Mazza C, Tanghetti B, and Tarenzi L
- Subjects
- Adolescent, Brain Neoplasms drug therapy, Brain Neoplasms radiotherapy, Brain Neoplasms surgery, Cerebrospinal Fluid Shunts, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Infant, Lomustine therapeutic use, Male, Prognosis, Vincristine therapeutic use, Brain Neoplasms therapy
- Published
- 1979
43. Therapeutic approach to primary malignant epithelial tumors of the liver in childhood: results of the Italian retrospective study and literature survey.
- Author
-
Perilongo G, Carli M, Guglielmi M, De Bernardi B, Bellani FF, Paolucci G, Pianca C, Madon E, Calculli G, and Ceci A
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular radiotherapy, Carcinoma, Hepatocellular surgery, Child, Child, Preschool, Humans, Infant, Italy epidemiology, Liver Neoplasms drug therapy, Liver Neoplasms mortality, Liver Neoplasms radiotherapy, Liver Neoplasms surgery, Male, Prognosis, Remission Induction, Retrospective Studies, Survival Rate, Carcinoma, Hepatocellular therapy, Liver Neoplasms therapy
- Abstract
We analyzed the clinical features and treatment of 23 hepatoblastomas (HPBs) and 16 hepatocellular carcinomas (HPCs) occurring in patients less than 19 years old, admitted to the Italian retrospective multicentric study, conducted between 1983 and 1985, on childhood malignant hepatic tumors. The median ages of the patients with HPB and HPC at diagnosis were 22.34 months and 96.23 months, respectively, with a male/female ratio of 0.7 and 1.7, respectively. Fourteen HPBs (61%) and 5 HPCs (31%) achieved surgical complete remission (CR). Of these, 11 HPB and all 5 HPC are still in CR with a median follow-up of 36 months and 3.5 years, respectively. One HPB and 1 HPC became resectable after a primary course of cis-platinum alone in the case of HPB and used with VP-16 in the case of HPC. All of the 9 HPBs and 11 HPCs, who never achieved CR, died of disease at a median interval from diagnosis of 5 and 2 months, respectively. The published therapeutic approaches for these tumors were also reviewed.
- Published
- 1987
- Full Text
- View/download PDF
44. [Behavior of phosphoisomerase and lactate dehydrogenase in pediatric oncological pathology].
- Author
-
Calculli G, Vaglia A, Astori L, Prandini BD, and Speziali G
- Subjects
- Child, Ependymoma enzymology, Female, Hodgkin Disease enzymology, Humans, Leukemia, Lymphoid enzymology, Leukemia, Myeloid, Acute enzymology, Male, Medulloblastoma enzymology, Neoplasm Metastasis enzymology, Neoplasm Recurrence, Local enzymology, Neuroblastoma enzymology, Prognosis, Sarcoma, Ewing enzymology, Wilms Tumor enzymology, Glucose-6-Phosphate Isomerase blood, L-Lactate Dehydrogenase blood, Leukemia enzymology, Neoplasms enzymology
- Abstract
Two glycolytic enzymes, PHI and LDH, have been evaluated in 18 children affected by leukemia or solid tumors: 11 patients had just initiated therapy, 3 patients were about to initiate therapy, while 4 patients were out of therapy. The analysis of the data obtained has shown a good correlation with the course of the disease: we have found values above the normal range in patients with a favorable course of the disease (bone marrow relapse or CNS involvement in leukemic children; relapse or metastasis in solid tumors) almost always before it was possible to demonstrate by clinical and laboratory studies the inhanchement of tumoral cells growth. This was true in all patients except two children affected by neuroblastoma, who were in a favorable immunological status (presence in the serum of free specific antibodies), and who were out of therapy. In these patients the abnormal high values of PHI were interpretated as an index of necrotic phenomena of micrometastasis of tumor cells induced by specific committed T-lymphocytes. Values of PHI and LDH in the normal range were found in patients whose disease demonstrated a favorable course. The AA. suggest the introduction of these enzymatic parameters which may be a useful index of the efficacy of the chemotherapy in the follow-up of oncologic patients.
- Published
- 1979
45. [Clinico-statistical correlations between the Apgar index and pathology of the placenta].
- Author
-
Basile F, Bini P, Leone L, and Calculli G
- Subjects
- Adult, Female, Fetal Diseases etiology, Humans, Infant, Newborn, Pregnancy, Apgar Score, Infant, Newborn, Diseases etiology, Placenta Diseases complications
- Published
- 1975
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.